KAPA Kairos Pharma, Ltd.
Company Updates ·
Kairos Pharma says median progression-free survival was 17.7 months with ENV-105 plus apalutamide, compared with 2 months on apalutamide alone, and has changed the trial to enroll patients earlier.
Split-adjusted shares will trade under the existing KAPA symbol at market open on September 1, 2026, and the company says the split is meant to help it keep its NYSE American listing.
The collaboration will evaluate ENV-105 with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer involving bone, and the company cites a $570M to $1.3B addressable global market.
The company reports no serious adverse events, defined as Grade 3 or higher, in 13 patients treated with ENV-105 and osimertinib, and says the safety profile supports progression toward an early efficacy readout.
Kairos Pharma has signed a term sheet to acquire worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor, from privately held Celyn Therapeutics, Inc., and has listed the milestones it expects for the rest of 2026.
The company expects to file within the 15-day extension period after its accounting staff finalizes the statements.
Kairos Pharma (NYSE American: KAPA) sold 2,500,000 pre-funded units, each with a common warrant at $1.40 per share. Boustead Securities and D. Boral Capital were co-placement agents.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome immune suppression and drug resistance. Its candidates include antibodies and small molecules for prostate cancer, lung cancer, breast cancer and glioblastoma, and the company describes a seven-drug portfolio. Its proprietary technologies are licensed from Cedars-Sinai Medical Center. Through its Enviro Therapeutics, Inc. subsidiary, acquired in June 2021, it holds ENV 105, a biologic that targets endoglin and is designed to address resistance to androgen targeted drugs and EGFR inhibitors, and ENV 205, a pre-clinical therapeutic for chemotherapy resistance and cachexia. ENV 105 is in a Phase 1 trial for non-small cell lung cancer and a randomized Phase 2 trial for prostate cancer, both started in September 2023. An earlier Phase 2 trial at Cedars-Sinai in heavily pre-treated prostate cancer patients reported a clinical benefit rate of 62%, and enrollment closed before the planned 40 patients because of limited drug supply. KROS 201, a T cell therapy for glioblastoma, is also in clinical trials. KROS 101 is a small molecule that targets the GITR ligand.
| Product or program | What it is | Stage |
|---|---|---|
| ENV 105 | Biologic targeting endoglin, for resistance to androgen targeted drugs and EGFR inhibitors | Phase 1 in non-small cell lung cancer; randomized Phase 2 in prostate cancer |
| KROS 201 | Activated T cell therapy for glioblastoma | Clinical trial started fall 2023 |
| KROS 101 | Small molecule that targets the GITR ligand | Pre-clinical or clinical-trial stage |
| ENV 205 | Therapeutic for chemotherapy resistance and cachexia | Pre-clinical |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.1 million | $414,000 |
| Net income (loss) | -$5.4 million | -$2.6 million |
| Cash from operations | -$3.4 million | -$4.0 million |
| Cash and equivalents | $4.5 million | $1.3 million |
Our latest story on this, dated Aug 21, 2026: "Kairos Pharma sets 1-for-7 reverse stock split effective September 1, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 17, 2025: "Kairos Pharma closes $3,497,500 private placement of pre-funded units and warrants". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 4, 2026: "Kairos Pharma signs CL-741 term sheet and lists milestones for 2026". The story links the filing or release it is based on. Read the story.
Kairos Pharma, Ltd. trades under the ticker KAPA on AMEX.
Kairos Pharma, Ltd. is listed on AMEX.
The SEC Central Index Key (CIK) for Kairos Pharma, Ltd. is 1962011. Its filings are on SEC EDGAR.
23,697,683 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Kairos Pharma, Ltd. under United States.
Our directory classifies Kairos Pharma, Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Kairos Pharma, Ltd. is US48301N2036.
aibio.space lists Kairos Pharma, Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome immune suppression and drug resistance. Its candidates include antibodies and small molecules for prostate cancer, lung cancer, breast cancer and glioblastoma, and the company describes a seven-drug portfolio.
ENV 105: Biologic targeting endoglin, for resistance to androgen targeted drugs and EGFR inhibitors Stage: Phase 1 in non-small cell lung cancer; randomized Phase 2 in prostate cancer.
KROS 201: Activated T cell therapy for glioblastoma Stage: Clinical trial started fall 2023.
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio